Description of the Working Group

Aim of the working group:

The aim of the working group is to improve the symptomatic treatment of Huntington`s disease patients and to establish treatments for HD with studies that fullfil the criteria of fact based medicine. Valuable data of symptomatic treatment are important not only to improve patient care but also to standardized the treatment. This standardisation will facilitate neuroprotective treatment trials, because it will reduce variability of the possible outcome measurements.

First steps

In the first steps the WG will conduct open label studies and screen epidemiological data from REGISTRY to get an overview in the used medication in HD care and to get an overview in the effects of  compounds for specific indication lile irritability, hyperkinesia, bradykinesia and apathy .

Next steps

In the following steps the WG will conduct controled trials in order to establish the therapies, that are identified by the first steps.
Besides medication therapie the WG will look on cotherapies like phyisiotherapy and speech therapy.

Lead Facilitator:

Dr. Daniel Ecker
Study Physician, Lead Facilitator Symp Focus Clinical Drug Development GmbH
Postal address:		Stresemannallee 6 41460 Neuss Deutschland
phone:		+49 2131 155409
e-mail:

Prof. Dr. Josef Priller
Principal Investigator EHDI Study, Lead Facilitator Symp, Motor Rater Cognitive Rater Psychiatric Behavioural Rater Charité - Universitätsmedizin Berlin, Klinik und Poliklinik für Neurologie, Klinik für Psychiatrie und Psychotherapie
Postal address:		Schumannstraße 20/21 10117 Berlin Deutschland
phone:		+49 30 450560227
fax:		+49 30 450560912
pager:		+49 30 450617209
e-mail:

Links

• Meetings
  
• Documents (login required)

• HSG Working Group - Clinical Trial Initiatives